Objective: Our study was aimed at analyzing the role of microRNA as a potential biomarker of PD.

Background: A substantial part of cases of Parkinson’s disease (PD) is misdiagnosed even in the practice of movement disorders specialists. Fluid biomarkers might be of value for clinicians and researchers to diagnose PD more accurately at different stages. According to recent studies, several microRNAs showed different expression in PD and healthy controls and could be associated with some clinical features of the disease.

Method: We recruited 70 patients with PD and 30 age- and sex-matched healthy controls. We assessed PD patients by UPDRS scale and HADS score. Expression of miR-7-5p, miR-146a-5p, miR-106a-5p, miR-185-5p, and miR-30c-5p was measured in blood leukocytes using reverse transcription followed by real-time PCR.

Results: We found no significant difference in the expression of the studied microRNAs between the PD and control groups. There was a significant negative correlation between miR-7-5p expression and UPDRS-I (R=-0,3, p=0,02), and a significant positive correlation between miR-185-5p and UPDRS-II (R=0,3, p=0,04). Treatment with dopamine receptor agonists and amantadine increased miR-7-5p expression in PD patients (p=0,019 and p=0,049, respectively).

Conclusion: Our results showed that the studied microRNAs could not be used as diagnostic tools in patients with PD, but miR-7-5p and miR-185-5p could be considered as relevant PD biomarkers associated with clinical findings and response to treatment.

« Back to MDS Virtual Congress 2021

MDS Abstracts - https://www.mdsabstracts.org/abstract/micrornas-as-a-potential-biomarker-of-parkinsons-disease/